Compare Amgen, Inc. (AMGN) vs Philip Morris International Inc. (PM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Philip Morris International Inc. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Philip Morris International Inc. trades at $181.83 (market cap $283.07B). The key difference: Philip Morris International Inc. is the larger of the two by market cap, and Philip Morris International Inc. pays the higher dividend (3.24%). Which is the better fit depends on your goals.
| AMGN | PM | |
|---|---|---|
Market Cap | $196.12B | $283.07B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $191.86 |
52-Week Low | $271.18 | $144.33 |
Enterprise Value | $241.41B | $329.56B |
Dividend Yield | 2.77% | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Philip Morris International (PM) trades at $181.62, up 0.25% today, near the analyst consensus price target of $194. The stock shows a bullish technical trend with support at $179 and resistance at $185. Recent Q1 2026 earnings beat expectations at $1.96 EPS versus $1.86, though Q4 2025 missed. Revenue grew to $40.65B in 2025 with a strong net margin of 26.74%. The company announced a $1.47 dividend payable July 20, 2026, but cut its 2026 profit forecast due to a $500M impairment and cost pressures.
Outlook remains positive with 68% analyst buy ratings, but risks include rising illicit cigarette trade in Europe, currency volatility, and consumer spending constraints. The stock offers value with a P/E of 25.57 and stable cash flows, though high debt levels and regulatory challenges require monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
